AbbVie lowers Q4, 2024 EPS estimates by $0.88

AbbVie (NYSE:ABBV) said it now expects to report acquired IPR&D and milestone expenses of $1.6B on a pre-tax basis for Q4, which will lower GAAP and non-GAAP earnings by $0.88 per share.

The drugmaker said it now sees reporting 2024